

SPECIALTY GUIDELINE MANAGEMENT

CINQAIR (reslizumab)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Cinqair is indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype.

Limitations of Use:

- Not for treatment of other eosinophilic conditions.
- Not for the relief of acute bronchospasm or status asthmaticus.

All other indications are considered experimental/investigational and are not a covered benefit.

II. CRITERIA FOR INITIAL APPROVAL

Authorization of 12 months may be granted for treatment of eosinophilic asthma when ALL of the following criteria are met:

- A. Member is 18 years of age or older
- B. Member has baseline blood eosinophil count of at least 400 cells per microliter
- C. Member has a history of severe asthma despite current treatment with both of the following medications at optimized doses:
 1. Inhaled corticosteroid
 2. Additional controller (long acting beta₂-agonist, leukotriene modifier, or sustained-release theophylline)

III. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for treatment of eosinophilic asthma when ALL of the following criteria are met:

- A. Member is 18 years of age or older
- B. Asthma control has improved on Cinqair treatment, demonstrated by a reduction in the frequency and/or severity of symptoms and exacerbations

IV. REFERENCES

1. Cinqair [package insert]. Frazer, PA: Teva Pharmaceuticals, Inc.; May 2016.
2. Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. *Lancet Respir Med.* 2015;3(5):355-366.

Cinqair SGM P2017

CVS Caremark is an independent company that provides pharmacy benefit management services to CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. members.

CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, Inc. and Group Hospitalization and Medical Services, Inc. CareFirst of Maryland, Inc., Group Hospitalization and Medical Services, Inc., CareFirst BlueChoice, Inc., The Dental Network and First Care, Inc. are independent licensees of the Blue Cross and Blue Shield Association. In the District of Columbia and Maryland, CareFirst MedPlus is the business name of First Care, Inc. In Virginia, CareFirst MedPlus is the business name of First Care, Inc. of Maryland (used in VA by: First Care, Inc.). © Registered trademark of the Blue Cross and Blue Shield Association

3. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2017 update. <http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/>. Accessed March 2, 2017.